Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment modalities and adolescent PCOS risk in girls with CPP or early fast puberty
ChiCTR2500099277Phase 4Not yet recruiting
- Sponsor
- Suzhou Science and Technology Town Hospital
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin in central precocious puberty (CPP), precocious puberty and polycystic ovary syndrome (PCOS) (3 arms), sponsored by Suzhou Science and Technology Town Hospital. Primary endpoint: Incidence of adolescent polycystic ovary syndrome. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
central precocious puberty (CPP)precocious pubertypolycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2500099277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099277.